Envestnet Asset Management Inc. Has $1.53 Million Holdings in Twist Bioscience Corporation $TWST

Envestnet Asset Management Inc. decreased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 40.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,594 shares of the company’s stock after selling 28,685 shares during the period. Envestnet Asset Management Inc. owned approximately 0.07% of Twist Bioscience worth $1,530,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TWST. ARK Investment Management LLC grew its position in Twist Bioscience by 2.5% in the 2nd quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company’s stock worth $235,472,000 after purchasing an additional 158,846 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Twist Bioscience by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock valued at $230,356,000 after buying an additional 60,276 shares during the period. William Blair Investment Management LLC grew its position in Twist Bioscience by 2.6% during the second quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company’s stock worth $143,724,000 after buying an additional 99,737 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock worth $95,883,000 after buying an additional 1,588,587 shares in the last quarter. Finally, EdgePoint Investment Group Inc. bought a new position in Twist Bioscience during the first quarter valued at about $43,705,000.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $25.45 on Thursday. The firm has a market capitalization of $1.56 billion, a P/E ratio of -19.43 and a beta of 2.43. The stock has a fifty day moving average price of $29.79 and a two-hundred day moving average price of $31.08. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.60.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%. Twist Bioscience has set its Q1 2026 guidance at EPS. FY 2026 guidance at EPS. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TWST shares. Barclays decreased their price objective on Twist Bioscience from $40.00 to $37.00 and set an “overweight” rating on the stock in a report on Monday. Evercore ISI reduced their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Twist Bioscience in a research note on Thursday, November 13th. Stephens began coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.50.

Insider Activity

In related news, CAO Robert F. Werner sold 1,016 shares of the stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $31,943.04. Following the sale, the chief accounting officer directly owned 51,030 shares in the company, valued at $1,604,383.20. This represents a 1.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paula Green sold 1,084 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $34,774.72. Following the sale, the senior vice president directly owned 142,187 shares of the company’s stock, valued at $4,561,358.96. This represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 122,865 shares of company stock valued at $3,879,926. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.